Nkarta, Inc. Operating Income
Nkarta, Inc. (NKTX) reported Operating Income of -$43.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- Nkarta, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$43.13M.
- Nkarta, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$30.88M.
- Nkarta, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$30.96M.
- Nkarta, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$27.29M.
- Nkarta, Inc. operating income (loss) for fiscal 2025 was -$122.00M.
- Nkarta, Inc. operating income (loss) for fiscal 2024 was -$128.19M.
- Nkarta, Inc. operating income (loss) for fiscal 2023 was -$131.65M.
- Nkarta, Inc. operating income (loss) for fiscal 2022 was -$118.95M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$43.13M 10-Q · filed 2026-08-10 | -$74.00M 10-Q · filed 2026-08-10 | -$104.97M derived: sum of 3 quarters · filed 2026-08-10 | -$132.25M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$30.88M 10-Q · filed 2026-05-12 | -$61.84M derived: sum of 2 quarters · filed 2026-05-12 | -$89.12M derived: sum of 3 quarters · filed 2026-05-12 | -$116.31M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$30.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$58.25M derived: sum of 2 quarters · filed 2026-03-25 | -$85.43M derived: sum of 3 quarters · filed 2026-08-10 | -$122.00M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | -$27.29M 10-Q · filed 2025-11-10 | -$54.47M derived: sum of 2 quarters · filed 2026-08-10 | -$91.04M 10-Q · filed 2025-11-10 | -$121.96M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$27.19M 10-Q · filed 2026-08-10 | -$63.75M 10-Q · filed 2026-08-10 | -$94.67M derived: sum of 3 quarters · filed 2026-08-10 | -$128.47M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$36.56M 10-Q · filed 2026-05-12 | -$67.49M derived: sum of 2 quarters · filed 2026-05-12 | -$101.28M derived: sum of 3 quarters · filed 2026-05-12 | -$132.00M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$30.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$64.72M derived: sum of 2 quarters · filed 2026-03-25 | -$95.43M derived: sum of 3 quarters · filed 2026-03-25 | -$128.19M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | -$33.79M 10-Q · filed 2025-11-10 | -$64.51M derived: sum of 2 quarters · filed 2025-11-10 | -$97.27M 10-Q · filed 2025-11-10 | -$128.46M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | -$30.71M 10-Q · filed 2025-08-12 | -$63.48M 10-Q · filed 2025-08-12 | -$94.66M derived: sum of 3 quarters · filed 2025-08-12 | -$123.96M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | -$32.76M 10-Q · filed 2025-05-14 | -$63.95M derived: sum of 2 quarters · filed 2025-05-14 | -$93.24M derived: sum of 3 quarters · filed 2025-05-14 | -$130.10M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$31.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$60.48M derived: sum of 2 quarters · filed 2025-03-26 | -$97.34M derived: sum of 3 quarters · filed 2025-03-26 | -$131.65M 10-K · filed 2025-03-26 | ||
| 2023-09-30 | -$29.29M 10-Q · filed 2024-11-07 | -$66.15M derived: sum of 2 quarters · filed 2024-11-07 | -$100.47M 10-Q · filed 2024-11-07 | -$135.45M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | -$36.86M 10-Q · filed 2024-08-13 | -$71.17M 10-Q · filed 2024-08-13 | -$106.15M derived: sum of 3 quarters · filed 2024-08-13 | -$136.42M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$34.31M 10-Q · filed 2024-05-09 | -$69.30M derived: sum of 2 quarters · filed 2024-05-09 | -$99.56M derived: sum of 3 quarters · filed 2024-05-09 | -$127.17M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$65.25M derived: sum of 2 quarters · filed 2024-03-21 | -$92.86M derived: sum of 3 quarters · filed 2024-03-21 | -$118.95M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | -$30.26M 10-Q · filed 2023-11-09 | -$57.87M derived: sum of 2 quarters · filed 2023-11-09 | -$83.97M 10-Q · filed 2023-11-09 | -$106.86M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$27.61M 10-Q · filed 2023-08-10 | -$53.71M 10-Q · filed 2023-08-10 | -$76.60M derived: sum of 3 quarters · filed 2023-08-10 | -$99.03M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$26.10M 10-Q · filed 2023-05-11 | -$48.98M derived: sum of 2 quarters · filed 2023-05-11 | -$71.41M derived: sum of 3 quarters · filed 2023-05-11 | -$93.05M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$22.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$45.31M derived: sum of 2 quarters · filed 2023-03-16 | -$66.95M derived: sum of 3 quarters · filed 2023-03-16 | -$86.43M 10-K · filed 2023-03-16 | ||
| 2021-09-30 | -$22.43M 10-Q · filed 2022-11-09 | -$44.06M derived: sum of 2 quarters · filed 2022-11-09 | -$63.54M 10-Q · filed 2022-11-09 | -$81.54M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$21.63M 10-Q · filed 2022-08-11 | -$41.11M 10-Q · filed 2022-08-11 | -$59.11M derived: sum of 3 quarters · filed 2022-08-11 | -$72.86M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$19.48M 10-Q · filed 2022-05-12 | -$37.48M derived: sum of 2 quarters · filed 2022-05-12 | -$51.23M derived: sum of 3 quarters · filed 2022-05-12 | -$61.58M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$31.74M derived: sum of 2 quarters · filed 2022-03-17 | -$42.10M derived: sum of 3 quarters · filed 2022-03-17 | -$51.51M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | -$13.75M 10-Q · filed 2021-11-10 | -$24.10M derived: sum of 2 quarters · filed 2021-11-10 | -$33.51M 10-Q · filed 2021-11-10 | -$42.16M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | -$10.36M 10-Q · filed 2021-08-12 | -$10.36M 10-Q · filed 2020-08-20 | -$19.76M 10-Q · filed 2021-08-12 | -$19.76M 10-Q · filed 2020-08-20 | -$28.41M derived: sum of 3 quarters · filed 2021-08-12 | -$34.32M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$9.41M 10-Q · filed 2021-05-13 | -$18.06M derived: sum of 2 quarters · filed 2021-05-13 | -$23.96M derived: sum of 3 quarters · filed 2021-05-13 | -$28.64M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$14.56M derived: sum of 2 quarters · filed 2021-03-25 | -$19.23M derived: sum of 3 quarters · filed 2021-03-25 | -$22.35M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$5.91M 10-Q · filed 2020-11-12 | -$10.58M derived: sum of 2 quarters · filed 2020-11-12 | -$13.70M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$4.67M 10-Q · filed 2020-08-20 | -$7.79M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |